ClinicalTrials.gov record
Completed Phase 2 Interventional

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

ClinicalTrials.gov ID: NCT01234935

Public ClinicalTrials.gov record NCT01234935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma

Study identification

NCT ID
NCT01234935
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Translational Oncology Research International
Other
Enrollment
8 participants

Conditions and interventions

Interventions

  • dasatinib Drug
  • gemcitabine hydrochloride Drug
  • immunohistochemistry staining method Other
  • laboratory biomarker analysis Other
  • mutation analysis Genetic
  • nucleic acid sequencing Genetic

Drug · Other · Genetic

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 12, 2011
Primary completion
Nov 26, 2017
Completion
Nov 26, 2017
Last update posted
Jan 8, 2018

2011 – 2017

United States locations

U.S. sites
17
U.S. states
4
U.S. cities
15
Facility City State ZIP Site status
Central Hematology Oncology Medical Group, Inc. Alhambra California 91801
TORI FULLERTON (St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center) Fullerton California 92835
Pacific Shores Medical Group Long Beach California 90813
UCLA medical center Los Angeles California 90024-3417
Translational Oncology Research International (TORI) Network Los Angeles California 90095
TORI NORTHRIDGE (North Valley Hematology/Oncology Medical Group) Northridge California 91325
UCLA Pasadena Pasadena California
TORI Inland Valley (Wilshire Oncology Medical Group, Inc. ) Pomona California 91767
TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.) Redondo Beach California 90277
TORI SANTA BARBARA I (Santa Barbara Hematology Oncology Medical Group, Inc.) Santa Barbara California 93105
TORI SANTA BARBARA II (SANSUM Clinic) Santa Barbara California 93105
TORI SANTA MARIA (Central Coast Medical Oncology Corporation) Santa Maria California 93454
UCLA Valencia Valencia California
Suburban Hematology-Oncology Associates, P.A. Lawrenceville Georgia 30045
Northwest Georgia Oncology Centers, P.C. Marietta Georgia 30060
Chevy Chase Healthcare Management, LLC Chevy Chase Maryland 20815
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01234935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2018 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01234935 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →